Cliff Lane, National Institutes of Health, discusses the most recent studies in the use of Interleukin-2 in boosting CD-4+ cells and the clinical outcomes for people with HIV.
He also explains the differences between the innate an adaptive immune systems.

Interviewed at the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009.

свернуть